Skip to main content
Minh Truong Do on Muck Rack

Minh Truong Do

As seen in: Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Minh

Contact Minh, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

RAS -ing the bar in the treatment of KRAS -mutant cholangiocarcinoma

|
By Minh Truong Do, Ferdinandos Skoulidis
| Cell Press Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Banales, J.M. ∙ Rodrigues, P.M. ∙ Affò, S. ... Cholangiocarcinoma 2026: status quo, unmet needs and priorities Nat. Rev. Gastroenterol. Hepatol. 2026; 23:65-96 2. Sang, B. ∙ Ye, L.F. ∙ Hu, F. ... Mechanisms of resistance to active state selective tri-complex RAS inhibitors Preprint at bioRxiv. 2025; 3. Entrialgo-Cadierno, R. ∙ Morali, K. ∙ Feliu, I. ... Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma Cancer Cell.
Open in Who Shared Issue with article?

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer

|
By Ana Galan-Cobo, Natalie I. Vokes, Yu Qian, David P Molkentine, Kavya Ramkumar, Alvaro G. Paula, Marlese Pisegna, Daniel J. McGrail, Alissa Poteete, Sungnam Cho, Minh Truong Do, Amirali Karimi, Yifan Kong, Anisha Solanki, Ankur Karmokar, Nicolas Floc’h, Adina M. Hughes, Rebecca Sargeant Verified, Lucy Young, Li Shen, Gozde Kar, Caezaan Keshvani, Claudio Arrechedera, Sharia Hernandez, Katharina Schlacher, Jing Wang, Sonia Iyer, James Conway, Mohamed Reda Keddar, Marta Milo, Ilario De Toma, Susan Critchlow, J. Carl Barrett, Jan Cosaert, Alan Lau Verified, Viia Valge-Archer, Lauren A Byers, Simon T. Barry, John Heymach
| Cell Press Verified
Keywords lung cancer NSCLC STK11 LKB1 KEAP1 DDR ATR inhibition ceralasertib immunotherapy Introduction KEAP1 is the third most commonly mutated tumor suppressor in lung adenocarcinoma (LUAD), and alterations in this gene commonly co-occur with KRAS activating mutations,1 the most prevalent oncogenic driver event in LUAD.2 KEAP1 is a negative regulator of NRF2, a master transcription factor that regulates anti-oxidative stress response.3 Thus, inactivating mutations in KEAP1 or activating...
Open in Who Shared Issue with article?
See all 2 articles